Search jobs 10-Apr-2021 Data at AACR Demonstrate Growing Clinical Utility of Guardant Health Liquid Biopsies in the Treatment and Management of Advanced Cancers
Phase 2 trial of Amgen’s investigational KRAS
G12C inhibitor, sotorasib, demonstrated comparable efficacy between patients identified as KRAS
G12C positive using Guardant360 CDx liquid biopsy or tissue biopsy
REDWOOD CITY, Calif. (BUSINESS WIRE) Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, presents new data at the AACR Virtual Annual Meeting I, April 10-15, 2021, highlighting the use of the company’s proprietary blood tests to advance precision oncology.
Key findings demonstrate the value of Guardant360